Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 22, No 3 (February 1), 2004: pp. 529-536
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.05.064
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Popat, S.
Right arrow Articles by Houlston, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Popat, S.
Right arrow Articles by Houlston, R. S.
Related Articles
Right arrowRelated Article
Right arrowRelated Correspondence

REVIEW ARTICLE

Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis

Sanjay Popat, Athena Matakidou, Richard S. Houlston

From the Section of Cancer Genetics, Institute of Cancer Research, Sutton, United Kingdom.

Address reprint requests to Sanjay Popat, MD, Section of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, UK; e-mail: s.popat{at}icr.ac.uk

PURPOSE: A number of studies have investigated the relationship between thymidylate synthase (TS) expression and survival in colorectal cancer (CRC) patients. Although most have reported poorer overall and progression-free survival with high TS expression, estimates of the hazard ratio (HR) between studies differ wildly. To derive a more precise estimate of the prognostic significance of TS expression, we have reviewed published studies and carried out a meta-analysis.

MATERIALS AND METHODS: Twenty studies stratifying overall survival and/or progression-free survival in CRC patients by TS expression status were eligible for analysis. The principal outcome measure was the HR. Data from these studies were pooled using standard meta-analysis techniques.

RESULTS: Thirteen studies investigated outcome in a total of 887 cases with advanced CRC, and seven studies investigated outcome in a total of 2,610 patients with localized CRC. A number of methods were used both to assess TS expression and to assign TS status. Sample sizes varied greatly, small sample sizes being a feature of the advanced disease studies. The combined HR estimate for overall survival (OS) was 1.74 (95% CI, 1.34 to 2.26) and 1.35 (95% CI, 1.07 to 1.80) in the advanced and adjuvant settings, respectively, but there was evidence of heterogeneity and possible publication bias.

CONCLUSION: Tumors expressing high levels of TS appeared to have a poorer OS compared with tumors expressing low levels. Additional studies with consistent methodology are needed to define the precise prognostic value of TS.

Supported by the United Kingdom Department of Health, the Alan Learner fund, and grants from Cancer Research UK and the Association for International Cancer Research.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Related Article

  • Thymidylate Synthase Expression in Colorectal Cancer: The Never-Ending Story
    Bruno Vincenzi, Daniele Santini, and Giuseppe Tonini
    JCO 2005 23: 2108 [Full Text]

Related Correspondence

  • Thymidylate Synthase Expression in Colorectal Cancer: The Never-Ending Story
    Bruno Vincenzi, Daniele Santini, and Giuseppe Tonini
    JCO 2005 23: 2108 [Full Text]


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
P. M. Wilson, W. Fazzone, M. J. LaBonte, J. Deng, N. Neamati, and R. D. Ladner
Novel opportunities for thymidylate metabolism as a therapeutic target
Mol. Cancer Ther., September 1, 2008; 7(9): 3029 - 3037.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Soong, N. Shah, M. Salto-Tellez, B. C. Tai, R. A. Soo, H. C. Han, S. S. Ng, W. L. Tan, N. Zeps, D. Joseph, et al.
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy
Ann. Onc., May 1, 2008; 19(5): 915 - 919.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Lee, C. K. Park, J. O. Park, T. Lim, Y. S. Park, H. Y. Lim, I. Lee, T. S. Sohn, J. H. Noh, J. S. Heo, et al.
Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy
Clin. Cancer Res., January 1, 2008; 14(1): 82 - 88.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ruzzo, F. Graziano, F. Loupakis, E. Rulli, E. Canestrari, D. Santini, V. Catalano, R. Ficarelli, P. Maltese, R. Bisonni, et al.
Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy
J. Clin. Oncol., April 1, 2007; 25(10): 1247 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Popat, Z Chen, D Zhao, H Pan, N Hearle, I Chandler, Y Shao, W Aherne, and R. Houlston
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer
Ann. Onc., December 1, 2006; 17(12): 1810 - 1817.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Y. Locker, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
J. Clin. Oncol., November 20, 2006; 24(33): 5313 - 5327.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Largillier, M.-C. Etienne-Grimaldi, J.-L. Formento, J. Ciccolini, J.-F. Nebbia, A. Ginot, M. Francoual, N. Renee, J.-M. Ferrero, C. Foa, et al.
Pharmacogenetics of capecitabine in advanced breast cancer patients.
Clin. Cancer Res., September 15, 2006; 12(18): 5496 - 5502.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Liersch, C. Langer, B. M. Ghadimi, B. Kulle, D. E. Aust, G. B. Baretton, W. Schwabe, P. Hausler, H. Becker, and C. Jakob
Lymph Node Status and TS Gene Expression Are Prognostic Markers in Stage II/III Rectal Cancer After Neoadjuvant Fluorouracil-Based Chemoradiotherapy
J. Clin. Oncol., September 1, 2006; 24(25): 4062 - 4068.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. Andre, D. Sargent, J. Tabernero, M. O'Connell, M. Buyse, A. Sobrero, J.-L. Misset, C. Boni, and A. de Gramont
Current Issues in Adjuvant Treatment of Stage II Colon Cancer
Ann. Surg. Oncol., June 1, 2006; 13(6): 887 - 898.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. A. Sinicrope, R. L. Rego, K. C. Halling, N. R. Foster, D. J. Sargent, B. La Plant, A. J. French, C. J. Allegra, J. A. Laurie, R. M. Goldberg, et al.
Thymidylate synthase expression in colon carcinomas with microsatellite instability.
Clin. Cancer Res., May 1, 2006; 12(9): 2738 - 2744.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ruzzo, F. Graziano, K. Kawakami, G. Watanabe, D. Santini, V. Catalano, R. Bisonni, E. Canestrari, R. Ficarelli, E. T. Menichetti, et al.
Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy
J. Clin. Oncol., April 20, 2006; 24(12): 1883 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Dotor, M. Cuatrecases, M. Martinez-Iniesta, M. Navarro, F. Vilardell, E. Guino, L. Pareja, A. Figueras, D. G. Mollevi, T. Serrano, et al.
Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment
J. Clin. Oncol., April 1, 2006; 24(10): 1603 - 1611.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Garcia, J. M. Garcia, C. Pena, J. Silva, G. Dominguez, A. Hurtado, I. Alonso, R. Rodriguez, M. Provencio, and F. Bonilla
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
Clin. Cancer Res., April 1, 2006; 12(7): 2095 - 2100.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Lyall, S. R. Dundas, S. Curran, and G. I. Murray
Profiling Markers of Prognosis in Colorectal Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1184 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. H. Smorenburg, G. J. Peters, C. J. van Groeningen, P. Noordhuis, K. Smid, A. M. G. H. van Riel, W. Dercksen, H. M. Pinedo, and G. Giaccone
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase
Ann. Onc., January 1, 2006; 17(1): 35 - 42.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, and G. M. Clark
Reporting Recommendations for Tumor Marker Prognostic Studies
J. Clin. Oncol., December 20, 2005; 23(36): 9067 - 9072.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Langer, K. Specht, K. Becker, P. Ewald, M. Bekesch, M. Sarbia, R. Busch, M. Feith, H. J. Stein, J.-R. Siewert, et al.
Association of Pretherapeutic Expression of Chemotherapy-Related Genes with Response to Neoadjuvant Chemotherapy in Barrett Carcinoma
Clin. Cancer Res., October 15, 2005; 11(20): 7462 - 7469.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Graziano and K. Kawakami
Studying the Predictive/Prognostic Role of Thymidylate Synthase Genotypes in Patients With Colorectal Cancer: Is One Polymorphism Enough?
J. Clin. Oncol., October 1, 2005; 23(28): 7230 - 7231.
[Full Text] [PDF]

Home page
 JCOHome page
J. D. Ahlgren
Thymidylate Synthase in Nodal Metastases: Prognostic for Chemosensitivity But Not for Adjuvant Therapy?
J. Clin. Oncol., August 20, 2005; 23(24): 5452 - 5454.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, G. M. Clark, and for the Statistics Subcommittee of the NCI-EORTC W
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
J Natl Cancer Inst, August 17, 2005; 97(16): 1180 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Ricciardiello, C. Ceccarelli, G. Angiolini, M. Pariali, P. Chieco, P. Paterini, G. Biasco, G. N. Martinelli, E. Roda, and F. Bazzoli
High Thymidylate Synthase Expression in Colorectal Cancer with Microsatellite Instability: Implications for Chemotherapeutic Strategies
Clin. Cancer Res., June 1, 2005; 11(11): 4234 - 4240.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kawakami, F. Graziano, G. Watanabe, A. Ruzzo, D. Santini, V. Catalano, R. Bisonni, F. Arduini, I. Bearzi, S. Cascinu, et al.
Prognostic Role of Thymidylate Synthase Polymorphisms in Gastric Cancer Patients Treated with Surgery and Adjuvant Chemotherapy
Clin. Cancer Res., May 15, 2005; 11(10): 3778 - 3783.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
S. Popat, R. Wort, and R. S. Houlston
Relationship Between Thymidylate Synthase (TS) Genotype and TS Expression: A Tissue Microarray Analysis of Colorectal Cancers
International Journal of Surgical Pathology, April 1, 2005; 13(2): 127 - 133.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Kidd, J. Yu, X. Li, W. D. Shannon, M. A. Watson, and H. L. McLeod
Variance in the Expression of 5-Fluorouracil Pathway Genes in Colorectal Cancer
Clin. Cancer Res., April 1, 2005; 11(7): 2612 - 2619.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. M. Ghadimi, M. Grade, M. J. Difilippantonio, S. Varma, R. Simon, C. Montagna, L. Fuzesi, C. Langer, H. Becker, T. Liersch, et al.
Effectiveness of Gene Expression Profiling for Response Prediction of Rectal Adenocarcinomas to Preoperative Chemoradiotherapy
J. Clin. Oncol., March 20, 2005; 23(9): 1826 - 1838.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Vincenzi, D. Santini, and G. Tonini
Thymidylate Synthase Expression in Colorectal Cancer: The Never-Ending Story
J. Clin. Oncol., March 20, 2005; 23(9): 2108 - 2108.
[Full Text] [PDF]

Home page
 JCOHome page
S. Popat, A. Matakidou, and R. S. Houlston
In Reply:
J. Clin. Oncol., March 20, 2005; 23(9): 2108 - 2109.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. J. Duffy
Predictive Markers in Breast and Other Cancers: A Review
Clin. Chem., March 1, 2005; 51(3): 494 - 503.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Popat, R. Hubner, and R.S. Houlston
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
J. Clin. Oncol., January 20, 2005; 23(3): 609 - 618.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Shichijo, K. Azuma, N. Komatsu, M. Ito, Y. Maeda, Y. Ishihara, and K. Itoh
Two Proliferation-Related Proteins, TYMS and PGK1, Could Be New Cytotoxic T Lymphocyte-Directed Tumor-Associated Antigens of HLA-A2+ Colon Cancer
Clin. Cancer Res., September 1, 2004; 10(17): 5828 - 5836.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Chan and D. J. Kerr
Can we individualise chemotherapy for colorectal cancer?
Ann. Onc., July 1, 2004; 15(7): 996 - 999.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online